Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index.

Abstract

Aim: To explore the prognostic value of the systemic inflammatory response index (SIRI) and peripheral blood T-cell subsets in patients with hepatocellular carcinoma (HCC) and the relationship between them. Materials & methods: We treated 352 patients with HCC with sorafenib and/or immune checkpoint inhibitors (ICIs) and analyzed SIRI and peripheral blood T cells. Results: SIRI was an independent prognostic factor for patients with HCC receiving systemic therapy. Patients with high SIRI and low baseline peripheral blood T-cell counts showed a poor response to ICIs. SIRI was significantly and negatively correlated with CD3+, CD4+ and CD8+ T-cell counts. Conclusion: SIRI markers can be employed to noninvasively assess the presence of cancer-promoting inflammation in the tumor microenvironment and predict the efficacy of targeted therapy and immunotherapy.

• Authors: Man Zhao, Xiaoling Duan, Lili Mi, Jianfei Shi, Ning Li, Xiaolei Yin, Xin Han, Jinfeng Wang, Guangjie Han, Jiaojiao Hou, Fei Yin
• Journal: Future oncology (London, England) (Future Oncol) Vol. 18 Issue 18 Pg. 2269-2288 (Jun 2022) ISSN: 1744-8301 [Electronic] England
• PMID: 35440159 (Publication Type: Journal Article)

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Carcinoma, Hepatocellular (pathology)
• Humans
• Immune Checkpoint Inhibitors
• Liver Neoplasms (pathology)
• Prognosis
• Systemic Inflammatory Response Syndrome (diagnosis, etiology)
• Tumor Microenvironment